$76.01 Million in Sales Expected for Hims & Hers Health, Inc. (NYSE:HIMS) This Quarter

Analysts forecast that Hims & Hers Health, Inc. (NYSE:HIMS) will announce $76.01 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Hims & Hers Health’s earnings, with estimates ranging from $75.75 million to $76.28 million. Hims & Hers Health reported sales of $41.47 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 83.3%. The company is scheduled to report its next earnings report on Thursday, March 17th.

On average, analysts expect that Hims & Hers Health will report full year sales of $263.19 million for the current financial year, with estimates ranging from $262.93 million to $263.46 million. For the next year, analysts expect that the business will post sales of $355.19 million, with estimates ranging from $353.30 million to $357.08 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Hims & Hers Health.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Wednesday, November 10th. The company reported ($0.09) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.05. Hims & Hers Health had a negative return on equity of 25.38% and a negative net margin of 35.74%. The company had revenue of $74.17 million during the quarter, compared to the consensus estimate of $70.10 million.

HIMS has been the subject of several research analyst reports. Citigroup lowered their target price on Hims & Hers Health from $14.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, December 20th. Piper Sandler upgraded Hims & Hers Health from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $10.00 to $12.00 in a report on Thursday, November 11th. Jefferies Financial Group assumed coverage on Hims & Hers Health in a report on Wednesday, December 1st. They set a “hold” rating and a $7.00 price target on the stock. Finally, Zacks Investment Research cut Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $12.11.

HIMS stock traded up $0.04 during midday trading on Friday, reaching $5.29. The company had a trading volume of 1,754,604 shares, compared to its average volume of 1,958,926. The company has a market capitalization of $1.08 billion and a price-to-earnings ratio of -9.80. The stock has a 50 day moving average price of $6.58 and a 200-day moving average price of $7.85. Hims & Hers Health has a 1-year low of $5.10 and a 1-year high of $25.40.

In related news, CEO Andrew Dudum bought 81,100 shares of the business’s stock in a transaction on Monday, December 13th. The stock was acquired at an average price of $5.93 per share, for a total transaction of $480,923.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Jack Abraham sold 1,000,000 shares of the firm’s stock in a transaction dated Tuesday, December 14th. The stock was sold at an average price of $5.55, for a total value of $5,550,000.00. The disclosure for this sale can be found here. 43.70% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. bought a new position in Hims & Hers Health during the 2nd quarter worth approximately $6,946,000. Cullinan Associates Inc. bought a new position in Hims & Hers Health during the 3rd quarter worth approximately $1,131,000. Legal & General Group Plc bought a new position in Hims & Hers Health during the 2nd quarter worth approximately $142,000. Credit Suisse AG bought a new position in Hims & Hers Health during the 2nd quarter worth approximately $1,429,000. Finally, Ieq Capital LLC bought a new position in Hims & Hers Health during the 3rd quarter worth approximately $467,000. 43.94% of the stock is currently owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available for purchase on its websites directly by customers. It provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, as well as cosmetics and supplement products, primarily focusing on wellness, sexual health, skincare, and hair care.

Featured Story: How does a 12b-1 fee affect fund performance?

Get a free copy of the Zacks research report on Hims & Hers Health (HIMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.